O

OmniAb Inc
NASDAQ:OABI

Watchlist Manager
OmniAb Inc
NASDAQ:OABI
Watchlist
Price: 1.9 USD 3.26% Market Closed
Market Cap: 273.5m USD

OmniAb Inc
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

OmniAb Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
O
OmniAb Inc
NASDAQ:OABI
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Non-Reccuring Items
-$543m
CAGR 3-Years
13%
CAGR 5-Years
-41%
CAGR 10-Years
-14%
Danaher Corp
NYSE:DHR
Non-Reccuring Items
-$105m
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Non-Reccuring Items
-$15.7m
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
-9%
Agilent Technologies Inc
NYSE:A
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Non-Reccuring Items
-$81m
CAGR 3-Years
-57%
CAGR 5-Years
3%
CAGR 10-Years
-8%
No Stocks Found

OmniAb Inc
Glance View

OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.

OABI Intrinsic Value
1.65 USD
Overvaluation 13%
Intrinsic Value
Price
O

See Also

Back to Top